New radiation approach aims to speed sarcoma recovery
NCT ID NCT04946357
First seen Mar 10, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 2 trial tests a shorter course of proton or carbon ion radiation (2-3 weeks instead of 5) given before surgery for extremity soft tissue sarcoma. The main goal is to see if this approach reduces wound healing problems after tumor removal. The study enrolls 42 adults with resectable sarcoma and no distant spread.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Heidelberg, Department of RadioOncology
RECRUITINGHeidelberg, Baden-Wurttemberg, 69120, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
proton or carbon ion radiation
What this could lead to
If successful, this shorter radiation schedule could become a new standard before sarcoma surgery, reducing side effects and improving quality of life.
What could go wrong
This is a small early-phase trial with only 42 participants, so results may not apply broadly. The main risk is wound healing problems after surgery, which the study is specifically measuring.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.